Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Johnson & Johnson (JNJ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow J&J's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
182.29 +2.63    +1.46%
24/06 - Closed. Currency in USD ( Disclaimer )
After Hours
182.29
0.00
0.00%
0:46:04 - Real-time Data
  • Volume: 9,144,113
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 179.98 - 182.53
Type:  Equity
Market:  United States
ISIN:  US4781601046 
CUSIP:  478160104
J&J 182.29 +2.63 +1.46%
  • General    
  • Chart    
  • News & Analysis    
  • Financials    
  • Technical    
  • Forum    
  • InvestingPro

For the three months ended 03 April 2022, Johnson & Johnson revenues increased 5% to $23.43B. Net income decreased 17% to $5.15B. Revenues reflect Pharmaceutical segment increase of 6% to $12.87B, Medical Devices segment increase of 6% to $6.97B, Europe segment increase of 11% to $6.02B, United States segment increase of 3% to $11.41B. Net income was offset by Acquisition and Integration related decrease from $600M (income) to $0K.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

JNJ Income Statement

Gross margin TTM 67.97%
Operating margin TTM 22.35%
Net Profit margin TTM 20.9%
Return on Investment TTM 14.88%
 Total Revenue  Net Income
Period Ending: Apr 03, 2022 Jan 02, 2022 Oct 03, 2021 Jul 04, 2021
Total Revenue 23426 24804 23338 23312
Gross Profit 15828 16849 16088 15725
Operating Income 5862 4836 3849 6662
Net Income 5149 4736 3667 6278

JNJ Balance Sheet

Quick Ratio MRQ 1.14
Current Ratio MRQ 1.39
LT Debt to Equity MRQ 38.62%
Total Debt to Equity MRQ 44.37%
 Total Assets  Total Liabilities
Period Ending: Apr 03, 2022 Jan 02, 2022 Oct 03, 2021 Jul 04, 2021
Total Assets 178355 182018 179228 176440
Total Liabilities 103646 107995 108956 106860
Total Equity 74709 74023 70272 69580

JNJ Cash Flow Statement

Cash Flow/Share TTM 10.14
Revenue/Share TTM 35.52
Operating Cash Flow  9.17%
 Cash  Net Change in Cash
Period Ending: Apr 03, 2022 Jan 02, 2022 Oct 03, 2021 Jul 04, 2021
Period Length: 0 Months 0 Months 9 Months 0 Months
Cash From Operating Activities 3979 23410 17678 9388
Cash From Investing Activities -3634 -8683 -3323 -604
Cash From Financing Activities -4385 -14047 -10611 -8404
Net Change in Cash -4024 502 3619 347
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JNJ Comments

Write your thoughts about Johnson & Johnson
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ifigeneia ifigeneia
ifigeneia ifigeneia Oct 15, 2021 16:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA approved finally. Few minutes ago!!!!
Lee Baldwin
Lee Baldwin Oct 15, 2021 16:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What?
Lukas Bednall
Lukas Bednall Sep 22, 2021 19:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Invested in J&J a couples years back and have closely followed the pharmaceutical industry. Found a company by the name of SpectrumX which has an IPO set for November. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trails for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
ifigeneia ifigeneia
ifigeneia ifigeneia Sep 22, 2021 19:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To entry in Spectrum or not? What do you think?
Adam Whipps
Adam Whipps Sep 22, 2021 19:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Checking it out looks like a good punt
Oc Masai
Oc Masai Apr 24, 2021 11:07
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job JNJ. move forward bullish
Lee Baldwin
Lee Baldwin Dec 29, 2020 15:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stock split???
Sinisa Galesic
Sinisa Galesic Dec 22, 2020 23:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Where we go next?
Paul Strong
Paul Strong Dec 22, 2020 23:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
AMC! But ultimately it’s your decision.
Lee Baldwin
Lee Baldwin Oct 29, 2020 16:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good buy. 0at this price
AdrianQ Khew
AdrianQ Khew Jul 23, 2019 11:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
JNJ is going to Make a strong come back tonight!
Bhavesh Parmar
Bhavesh Parmar Dec 17, 2018 1:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Immediate inquiry must be done
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email